Coherus Biosciences Stock Current Asset
| CHRS Stock | USD 1.18 0.02 1.72% |
Coherus BioSciences fundamentals help investors to digest information that contributes to Coherus BioSciences' financial success or failures. It also enables traders to predict the movement of Coherus Stock. The fundamental analysis module provides a way to measure Coherus BioSciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Coherus BioSciences stock.
At this time, Coherus BioSciences' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 42 M in 2025, whereas Total Current Assets are likely to drop slightly above 311.1 M in 2025. Coherus | Current Asset |
Coherus BioSciences Company Current Asset Analysis
Coherus BioSciences' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Coherus BioSciences Current Asset | 197.39 M |
Most of Coherus BioSciences' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Coherus BioSciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Coherus Current Asset Historical Pattern
Today, most investors in Coherus BioSciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Coherus BioSciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Coherus BioSciences current asset as a starting point in their analysis.
Coherus BioSciences Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Coherus Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Coherus BioSciences has a Current Asset of 197.39 M. This is 90.83% lower than that of the Biotechnology sector and 81.39% lower than that of the Health Care industry. The current asset for all United States stocks is 97.89% higher than that of the company.
Coherus Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Coherus BioSciences' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Coherus BioSciences could also be used in its relative valuation, which is a method of valuing Coherus BioSciences by comparing valuation metrics of similar companies.Coherus BioSciences is currently under evaluation in current asset category among its peers.
Coherus BioSciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Coherus BioSciences from analyzing Coherus BioSciences' financial statements. These drivers represent accounts that assess Coherus BioSciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Coherus BioSciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.2B | 1.2B | 614.8M | 313.6M | 282.2M | 518.3M | |
| Enterprise Value | 1.1B | 1.2B | 1.0B | 691.5M | 622.4M | 539.3M |
Coherus Fundamentals
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 308.94 M | ||||
| Shares Outstanding | 115.89 M | ||||
| Shares Owned By Insiders | 1.36 % | ||||
| Shares Owned By Institutions | 60.00 % | ||||
| Number Of Shares Shorted | 30.9 M | ||||
| Price To Earning | 4.22 X | ||||
| Price To Book | 73.19 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 257.24 M | ||||
| Gross Profit | 136.08 M | ||||
| EBITDA | (193.94 M) | ||||
| Net Income | (237.89 M) | ||||
| Cash And Equivalents | 275.48 M | ||||
| Cash Per Share | 3.54 X | ||||
| Total Debt | 480.84 M | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (174.88 M) | ||||
| Short Ratio | 12.41 X | ||||
| Earnings Per Share | (0.09) X | ||||
| Target Price | 5.9 | ||||
| Number Of Employees | 235 | ||||
| Beta | 0.81 | ||||
| Market Capitalization | 136.75 M | ||||
| Total Asset | 629.6 M | ||||
| Retained Earnings | (1.58 B) | ||||
| Working Capital | 143.86 M | ||||
| Current Asset | 197.39 M | ||||
| Current Liabilities | 106.02 M | ||||
| Net Asset | 629.6 M |
About Coherus BioSciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coherus BioSciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coherus BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coherus BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.